Santen Pharmaceutical
Corporate VCOsaka · Series A–Series C
Investment thesis
Santen Pharmaceutical is an Osaka, Japan-based pharmaceutical company specializing in ophthalmology, with operations in about 20 countries and products sold in more than 70. Alongside its core research, development, and commercialization business, it has made corporate venture investments in health-related startups across Series A through Series C rounds.
What they invest in
from 1 of 2 portfolio companiesBiotech ×1
HQs:United States×1
Investments · 2 tracked
founders shown can be your intro pathOther
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
International BioMedical DevicesRetroSense Therapeutics
Exits · 1
IPOs and acquisitions across the tracked portfolioRetroSense Therapeuticsacq. by Allergan
Frequently asked questions
- What stage does Santen Pharmaceutical invest at?
- Santen Pharmaceutical invests at the Series A, Series B, Series C stages.
- What sectors does Santen Pharmaceutical focus on?
- Santen Pharmaceutical focuses on Biotech, Healthtech, Medical Devices.
- Where is Santen Pharmaceutical located?
- Santen Pharmaceutical is headquartered in Osaka, JP.
Similar investors
ACT Venture Capital is an independent Irish venture capital firm that invests €1 million to €15 million in growth-stage private companies, with capacity for larger commitments through syndicated rounds.
Amadeus Capital Partners is a technology investment firm that backs founders building complex, science-led and deep tech businesses, supporting them over the long term as they scale internationally.
.jpeg){kind=logo}
B Capital is a global investment firm backing early to late-stage technology innovators across technology, healthcare, and energy & resilience sectors.
Breyer Capital is a venture capital firm that backs high-impact entrepreneurs, making strategic investments guided by founder passion and its network of experienced investors.
Capricorn Partners is a Belgium-based, partner-owned independent management company for alternative investment funds, investing in innovative companies across digital, health and clean technologies with an ESG focus.